Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:35 UTC |
---|
HMDB ID | HMDB0014350 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Pyrimethamine |
---|
Description | Pyrimethamine is only found in individuals that have used or taken this drug. It is one of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. [PubChem]Pyrimethamine inhibits the dihydrofolate reductase of plasmodia and thereby blocks the biosynthesis of purines and pyrimidines, which are essential for DNA synthesis and cell multiplication. This leads to failure of nuclear division at the time of schizont formation in erythrocytes and liver. |
---|
Structure | CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1 InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17) |
---|
Synonyms | Value | Source |
---|
2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine | ChEBI | 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine | ChEBI | 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine | ChEBI | 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine | ChEBI | 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine | ChEBI | 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine | ChEBI | CD | ChEBI | Chloridine | ChEBI | Chloridyn | ChEBI | Diaminopyritamin | ChEBI | Ethylpyrimidine | ChEBI | Pirimetamina | ChEBI | Primethamine | ChEBI | Pyrimethaminum | ChEBI | Daraprim | Kegg | Chloridin | HMDB | Pirimetamin | HMDB | Pyremethamine | HMDB | Pyrimethamin | HMDB | Glaxo wellcome brand OF pyrimethamine | HMDB | GlaxoSmithKline brand OF pyrimethamine | HMDB | Tindurine | HMDB | Aventis brand OF pyrimethamine | HMDB | Wellcome brand OF pyrimethamine | HMDB | Malocide | HMDB |
| Show more...
---|
Chemical Formula | C12H13ClN4 |
---|
Average Molecular Weight | 248.711 |
---|
Monoisotopic Molecular Weight | 248.082874143 |
---|
IUPAC Name | 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine |
---|
Traditional Name | pyrimethamine |
---|
CAS Registry Number | 58-14-0 |
---|
SMILES | CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1 |
---|
InChI Identifier | InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17) |
---|
InChI Key | WKSAUQYGYAYLPV-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as aminopyrimidines and derivatives. These are organic compounds containing an amino group attached to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazines |
---|
Sub Class | Pyrimidines and pyrimidine derivatives |
---|
Direct Parent | Aminopyrimidines and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Aminopyrimidine
- Chlorobenzene
- Halobenzene
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Hydropyrimidine
- Benzenoid
- Heteroaromatic compound
- Azacycle
- Organochloride
- Organohalogen compound
- Amine
- Hydrocarbon derivative
- Organopnictogen compound
- Organonitrogen compound
- Primary amine
- Organic nitrogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 233.5 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.18 g/L | Not Available | LogP | 2.7 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Pyrimethamine,1TMS,isomer #1 | CCC1=NC(N)=NC(N[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2395.8 | Semi standard non polar | 33892256 | Pyrimethamine,1TMS,isomer #1 | CCC1=NC(N)=NC(N[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2114.0 | Standard non polar | 33892256 | Pyrimethamine,1TMS,isomer #1 | CCC1=NC(N)=NC(N[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3446.8 | Standard polar | 33892256 | Pyrimethamine,1TMS,isomer #2 | CCC1=NC(N[Si](C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 2423.7 | Semi standard non polar | 33892256 | Pyrimethamine,1TMS,isomer #2 | CCC1=NC(N[Si](C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 2099.4 | Standard non polar | 33892256 | Pyrimethamine,1TMS,isomer #2 | CCC1=NC(N[Si](C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 3481.7 | Standard polar | 33892256 | Pyrimethamine,2TMS,isomer #1 | CCC1=NC(N[Si](C)(C)C)=NC(N[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2394.1 | Semi standard non polar | 33892256 | Pyrimethamine,2TMS,isomer #1 | CCC1=NC(N[Si](C)(C)C)=NC(N[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2194.4 | Standard non polar | 33892256 | Pyrimethamine,2TMS,isomer #1 | CCC1=NC(N[Si](C)(C)C)=NC(N[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3276.2 | Standard polar | 33892256 | Pyrimethamine,2TMS,isomer #2 | CCC1=NC(N)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2326.7 | Semi standard non polar | 33892256 | Pyrimethamine,2TMS,isomer #2 | CCC1=NC(N)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2315.1 | Standard non polar | 33892256 | Pyrimethamine,2TMS,isomer #2 | CCC1=NC(N)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3280.3 | Standard polar | 33892256 | Pyrimethamine,2TMS,isomer #3 | CCC1=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 2362.6 | Semi standard non polar | 33892256 | Pyrimethamine,2TMS,isomer #3 | CCC1=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 2294.0 | Standard non polar | 33892256 | Pyrimethamine,2TMS,isomer #3 | CCC1=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 3236.0 | Standard polar | 33892256 | Pyrimethamine,3TMS,isomer #1 | CCC1=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC(N[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2388.5 | Semi standard non polar | 33892256 | Pyrimethamine,3TMS,isomer #1 | CCC1=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC(N[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2363.8 | Standard non polar | 33892256 | Pyrimethamine,3TMS,isomer #1 | CCC1=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC(N[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2970.5 | Standard polar | 33892256 | Pyrimethamine,3TMS,isomer #2 | CCC1=NC(N[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2385.5 | Semi standard non polar | 33892256 | Pyrimethamine,3TMS,isomer #2 | CCC1=NC(N[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2346.8 | Standard non polar | 33892256 | Pyrimethamine,3TMS,isomer #2 | CCC1=NC(N[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3044.1 | Standard polar | 33892256 | Pyrimethamine,4TMS,isomer #1 | CCC1=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2451.5 | Semi standard non polar | 33892256 | Pyrimethamine,4TMS,isomer #1 | CCC1=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2518.6 | Standard non polar | 33892256 | Pyrimethamine,4TMS,isomer #1 | CCC1=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2799.1 | Standard polar | 33892256 | Pyrimethamine,1TBDMS,isomer #1 | CCC1=NC(N)=NC(N[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2560.2 | Semi standard non polar | 33892256 | Pyrimethamine,1TBDMS,isomer #1 | CCC1=NC(N)=NC(N[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2336.5 | Standard non polar | 33892256 | Pyrimethamine,1TBDMS,isomer #1 | CCC1=NC(N)=NC(N[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3466.6 | Standard polar | 33892256 | Pyrimethamine,1TBDMS,isomer #2 | CCC1=NC(N[Si](C)(C)C(C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 2580.3 | Semi standard non polar | 33892256 | Pyrimethamine,1TBDMS,isomer #2 | CCC1=NC(N[Si](C)(C)C(C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 2315.3 | Standard non polar | 33892256 | Pyrimethamine,1TBDMS,isomer #2 | CCC1=NC(N[Si](C)(C)C(C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 3474.8 | Standard polar | 33892256 | Pyrimethamine,2TBDMS,isomer #1 | CCC1=NC(N[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2748.4 | Semi standard non polar | 33892256 | Pyrimethamine,2TBDMS,isomer #1 | CCC1=NC(N[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2649.1 | Standard non polar | 33892256 | Pyrimethamine,2TBDMS,isomer #1 | CCC1=NC(N[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3329.3 | Standard polar | 33892256 | Pyrimethamine,2TBDMS,isomer #2 | CCC1=NC(N)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2712.8 | Semi standard non polar | 33892256 | Pyrimethamine,2TBDMS,isomer #2 | CCC1=NC(N)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2700.0 | Standard non polar | 33892256 | Pyrimethamine,2TBDMS,isomer #2 | CCC1=NC(N)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3312.0 | Standard polar | 33892256 | Pyrimethamine,2TBDMS,isomer #3 | CCC1=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 2727.7 | Semi standard non polar | 33892256 | Pyrimethamine,2TBDMS,isomer #3 | CCC1=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 2661.6 | Standard non polar | 33892256 | Pyrimethamine,2TBDMS,isomer #3 | CCC1=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC(N)=C1C1=CC=C(Cl)C=C1 | 3253.3 | Standard polar | 33892256 | Pyrimethamine,3TBDMS,isomer #1 | CCC1=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2947.3 | Semi standard non polar | 33892256 | Pyrimethamine,3TBDMS,isomer #1 | CCC1=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2959.1 | Standard non polar | 33892256 | Pyrimethamine,3TBDMS,isomer #1 | CCC1=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3173.9 | Standard polar | 33892256 | Pyrimethamine,3TBDMS,isomer #2 | CCC1=NC(N[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2958.9 | Semi standard non polar | 33892256 | Pyrimethamine,3TBDMS,isomer #2 | CCC1=NC(N[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 2947.6 | Standard non polar | 33892256 | Pyrimethamine,3TBDMS,isomer #2 | CCC1=NC(N[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3226.9 | Standard polar | 33892256 | Pyrimethamine,4TBDMS,isomer #1 | CCC1=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3178.8 | Semi standard non polar | 33892256 | Pyrimethamine,4TBDMS,isomer #1 | CCC1=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3222.2 | Standard non polar | 33892256 | Pyrimethamine,4TBDMS,isomer #1 | CCC1=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C1C1=CC=C(Cl)C=C1 | 3090.7 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Pyrimethamine CI-B (Non-derivatized) | splash10-0002-0090000000-4e966bed391e234a23e3 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Pyrimethamine CI-B (Non-derivatized) | splash10-0002-0090000000-4e966bed391e234a23e3 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyrimethamine GC-MS (Non-derivatized) - 70eV, Positive | splash10-01pk-0290000000-f67f41257c448ad0d840 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyrimethamine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0002-2590000000-6434b6f0181741b3ca41 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine LC-ESI-QTOF , positive-QTOF | splash10-0002-0090000000-a146b85d59fc9835ed4c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine LC-ESI-QTOF , positive-QTOF | splash10-0002-0090000000-84e4cea277c64351f21b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine LC-ESI-QTOF , positive-QTOF | splash10-0002-0190000000-d931593de00f33f04587 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine LC-ESI-QTOF , positive-QTOF | splash10-0059-0980000000-a232e355dd50976aea07 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine LC-ESI-QTOF , positive-QTOF | splash10-005a-0920000000-7d48f7cfecbd7823803a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine , positive-QTOF | splash10-0002-0290000000-b6d3f56ade24c0e6984c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine , positive-QTOF | splash10-0002-0290000000-415b60a9caab352df184 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine , positive-QTOF | splash10-0032-2960000000-583d00b81182f34e5a94 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 20V, Positive-QTOF | splash10-0002-0090000000-84e4cea277c64351f21b | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 10V, Positive-QTOF | splash10-0002-0090000000-a146b85d59fc9835ed4c | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 40V, Positive-QTOF | splash10-0059-0980000000-a232e355dd50976aea07 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 30V, Positive-QTOF | splash10-0002-0190000000-d931593de00f33f04587 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 30V, Positive-QTOF | splash10-0002-0090000000-a5bd8cb5be16b08fe352 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 45V, Positive-QTOF | splash10-0002-0090000000-ec976a2cca417c4abd83 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 15V, Positive-QTOF | splash10-0002-0090000000-142231cbd9fb9d4cd7ca | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 50V, Positive-QTOF | splash10-005a-0920000000-7d48f7cfecbd7823803a | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 90V, Positive-QTOF | splash10-005a-0910000000-74228f82abe0906b09dd | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 30V, Positive-QTOF | splash10-0002-0190000000-2277a786baa63a6f391c | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyrimethamine 50V, Positive-QTOF | splash10-005a-0920000000-aacf5c362f2e7330e364 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyrimethamine 10V, Positive-QTOF | splash10-0002-0090000000-cc03baac614916e188ae | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyrimethamine 20V, Positive-QTOF | splash10-0002-0190000000-8c90fdad9d6f513cfdcf | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyrimethamine 40V, Positive-QTOF | splash10-03ec-2940000000-ad7ab31613780bee7745 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyrimethamine 10V, Negative-QTOF | splash10-0002-0090000000-7cec7981debaccce56c0 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyrimethamine 20V, Negative-QTOF | splash10-0002-1190000000-3e6ac4ed3d9334756216 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyrimethamine 40V, Negative-QTOF | splash10-0006-9740000000-b92682f3660029c1045d | 2016-08-03 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00205 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00205 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00205 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 4819 |
---|
KEGG Compound ID | C07391 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Pyrimethamine |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 4993 |
---|
PDB ID | CP6 |
---|
ChEBI ID | 8673 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Sirichaiwat C, Intaraudom C, Kamchonwongpaisan S, Vanichtanankul J, Thebtaranonth Y, Yuthavong Y: Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. J Med Chem. 2004 Jan 15;47(2):345-54. [PubMed:14711307 ]
- Gatton ML, Martin LB, Cheng Q: Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum. Antimicrob Agents Chemother. 2004 Jun;48(6):2116-23. [PubMed:15155209 ]
|
---|